Share Prices & Company Research

Market News

02 Jun 2020 | 07:37

PureTech firm Gelesis gets Europe approval for 'Plenity'

(Sharecast News) - Clinical stage biotherapeutics company PureTech Health announced on Tuesday that its founded company Gelesis has received approval to market 'Plenity', a novel weight-loss treatment, in Europe.

The FTSE 250 company said Gelesis received a CE-mark for Plenity as a class 3 medical device, indicated for weight loss in overweight and obese adults with a body mass index of between 25 and 40, when used in conjunction with diet and exercise.

It said Gelesis would now be able to market Plenity throughout the European Economic Area and in other countries that recognise the CE mark.

Gelesis previously received clearance for Plenity from the US Food and Drug Administration (FDA), and planned to bring Plenity to the United States first, where it is now available to a limited extent while it ramps up its commercial operations and inventory for a broad launch in 2021.

"This is an important milestone for Gelesis and for the millions of adults across Europe who are seeking to manage their weight," said PureTech's chief innovation officer Eric Elenko.

"We look forward to continued progress from Gelesis' novel hydrogel platform and to the broad launch of Plenity across of the world."

At 0950 BST, shares in PureTech Health were up 2.2% at 255.5p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 15th January 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.